[Undesirable drug interactions. Notes on general principles].
Increasing knowledge about undersirable drug interactions make necessary new differential-therapeutic considerations. It is attempted to meet the problem in its general importance and - without any over-refinements which have nothing to do with practice - to draw conclusions for pharmacotherapy.
D000107:Acetylation; D001463:Barbiturates / Q000627:therapeutic use; D003374:Coumarins / Q000627:therapeutic use; D004336:Drug Antagonism; D004347:Drug Interactions; D004357:Drug Synergism; D006801:Humans; D007538:Isoniazid / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010653:Phenylbutazone / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use; D013810:Therapeutic Equivalency
D001463:Barbiturates; D003374:Coumarins; D008996:Monoamine Oxidase Inhibitors; D013566:Sympathomimetics; D010653:Phenylbutazone; D007538:Isoniazid
Unerwünschte Arneimittelinteraktionen. Prinzipielle Bemerkungen.